<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606446</url>
  </required_header>
  <id_info>
    <org_study_id>C4551001</org_study_id>
    <nct_id>NCT04606446</nct_id>
  </id_info>
  <brief_title>Study of PF-07248144 in Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>KAT6</acronym>
  <official_title>A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics&#xD;
      (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of&#xD;
      PF-07248144 as a single agent and in combination with either fulvestrant or letrozole +&#xD;
      palbociclib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study has two parts, Part 1 (dose escalation) and Part 2 (dose expansion). Part 1 is divided&#xD;
      into Parts 1A, 1B, and 1C and Part 2 is divided into Parts 2A and 2B. In Part 1A, single&#xD;
      escalating doses of PF-07248144 alone will be administered to determine the maximum tolerable&#xD;
      dose (MTD) and select the recommended dose for expansion (RP2D). In Part 1B and 1C,&#xD;
      PF-07248144 will be administered in combination with either fulvestrant or letrozole +&#xD;
      palbociclib.&#xD;
&#xD;
      After the determination of the monotherapy expansion RP2D in Part 1A, PF-07248144 will be&#xD;
      evaluated in a dose expansion cohort as a monotherapy in Part 2A. After determination of the&#xD;
      combination RP2D from Part 1B and Part 1C, PF-07248144 in combination with an either&#xD;
      fulvestrant (Part 1B) or letrozole + palbociclib (Part 1C) may be evaluated in Part 2B. The&#xD;
      specific combination partners that will be carried forward to Part 2B will be contingent upon&#xD;
      preclinical evidence, clinical safety and potential efficacy as well as PK and PD data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">April 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The dose escalation parts and the dose finding parts of the study will be guided by a Bayesian analysis of Cycle 1 dose-limiting toxicity (DLT) data for PF-07248144 as monotherapy or in combination with fulvestrant or with letrozole + palbociclib. A traditional 2-parameter Bayesian Logistic Regression Model (BLRM) will be used to model the DLT relationship of PF-07248144 monotherapy and a more complex BLRM model specifically designed for combinations will be used to model the dose toxicity relationship of PF-07248144 given in combination with fulvestrant or with letrozole + palbociclib.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicities in the Dose Esclation Arms.</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Esclation Arms.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Esclation Arms.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Dose: Maximum Observed Concentration (Cmax) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Dose: Time to Maximum concentration (Tmax) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Dose: AUC from time zero to time of last measurable concentration (AUClast) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single and Multiple Dose: Terminal Elimination half-life (t1/2) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Steady-State Cmax (Cmax,ss) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Steady-state Tmax (Tmax,ss) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Steady state AUC during a dosage interval (τ) (AUCτ,ss) in the Dose Esclation and Dose Finding Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Steady-state Cmin (Cmin,ss) in the Dose Esclation and Dose Finding Arms.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Steady-state apparent total clearance (CLss/F) in the Dose Esclation and Dose Finding Arms.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessments for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) in participants in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Respponse (DOR) in participants enrolled in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentrations of PF-07248144 for selected cycles in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessment for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations of PF-07248144 for selected cycles in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Pharmacokinetic (PK) assessment for PF-07248144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) in the participants in the food effect subset in monotherapy dose expansion arm</measure>
    <time_frame>Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
    <description>The effect of food on the PK of PF-07248144.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum concentration (Tmax) in the participants in the food effect subset in monotherapy dose expansion arm</measure>
    <time_frame>Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
    <description>The effect of food on the PK of PF-07248144.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to time of last measurable concentration (AUClast) in the participants in the food effect subset in monotherapy dose expansion arm</measure>
    <time_frame>Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
    <description>The effect of food on the PK of PF 07248144.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) observed in participants in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) observed in participants emrolled in the Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) observed in particiapants enrolled in Dose Expansion Arms</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Locally Advanced or Metastatic ER+ HER2- Breast Cancer</condition>
  <condition>Locally Advanced or Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Locally Advanced or Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1A Monotherapy Escalation Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 Monotherapy Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1A Monotherapy Escalation Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 Monotherapy Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1A Monotherapy Escalation Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 Monotherapy Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1A Monotherapy Escalation Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 Monotherapy Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B Combination Dose Finding Arm level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 with Fulvestrant Combination Dose Finding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B Combination Dose Finding Arm Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 with Fulvestrant Combination Dose Finding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1C Combination Dose Finding Arm Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 with Letrozole + Palbociclib Combination Dose Finding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1C Combination Dose FInding Arm Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 with Letrozole + Palbociclib Combination Dose Finding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A Monotherapy Dose Expansion Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 Monotherapy Dose Expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B Combination Dose Expansion Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07248144 with either Fulvestrant or Letrozole + Palbociclib Dose Expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07248144</intervention_name>
    <description>KAT6 Inhibitor</description>
    <arm_group_label>1A Monotherapy Escalation Dose Level 1</arm_group_label>
    <arm_group_label>1A Monotherapy Escalation Dose Level 2</arm_group_label>
    <arm_group_label>1A Monotherapy Escalation Dose Level 3</arm_group_label>
    <arm_group_label>1A Monotherapy Escalation Dose Level 4</arm_group_label>
    <arm_group_label>1B Combination Dose Finding Arm Level 2</arm_group_label>
    <arm_group_label>1B Combination Dose Finding Arm level 1</arm_group_label>
    <arm_group_label>1C Combination Dose FInding Arm Level 2</arm_group_label>
    <arm_group_label>1C Combination Dose Finding Arm Level 1</arm_group_label>
    <arm_group_label>2A Monotherapy Dose Expansion Arm</arm_group_label>
    <arm_group_label>2B Combination Dose Expansion Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Endocrine Therapy</description>
    <arm_group_label>1B Combination Dose Finding Arm level 1</arm_group_label>
    <arm_group_label>1C Combination Dose FInding Arm Level 2</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Endocrine Therapy</description>
    <arm_group_label>1B Combination Dose Finding Arm Level 2</arm_group_label>
    <arm_group_label>1C Combination Dose FInding Arm Level 2</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK4/6 Inhibitor</description>
    <arm_group_label>1B Combination Dose Finding Arm Level 2</arm_group_label>
    <arm_group_label>1C Combination Dose FInding Arm Level 2</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Characteristics - Breast, Prostate, and Lung Cancer&#xD;
&#xD;
               -  Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of&#xD;
                  locally advanced or metastatic ER+HER2- breast cancer, locally advanced or&#xD;
                  metastatic CRPC, or locally advanced or metastatic NSCLC that is intolerant or&#xD;
                  resistant to standard therapy or for which no standard therapy is available.&#xD;
&#xD;
               -  Part 1B and Part 1C (Combination Dose Escalation) Histological or cytological&#xD;
                  diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants&#xD;
                  must have progressed after at least 1 prior line of treatment with an endocrine&#xD;
                  therapy and CDK4/6 inhibitor in the advanced or metastatic setting.&#xD;
&#xD;
               -  Part 2A (ER+HER2- breast cancer 3L+, monotherapy) Histological or cytological&#xD;
                  diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants&#xD;
                  must have progressed after at least 1 prior line of CDK4/6 inhibitor and 2 lines&#xD;
                  of endocrine therapy.&#xD;
&#xD;
               -  Part 2B (ER+HER2- breast cancer 2L, combination) Histological or cytological&#xD;
                  diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants&#xD;
                  must have progressed after first line combination treatment with letrozole +&#xD;
                  palbociclib.&#xD;
&#xD;
               -  Participants with ER+HER2- advanced or metastatic breast cancer must have&#xD;
                  documentation of ER-positive tumor (≥1% positive stained cells) based on most&#xD;
                  recent tumor biopsy utilizing an assay consistent with local standards.&#xD;
&#xD;
               -  Participants with ER+HER2- advanced or metastatic breast cancer must have&#xD;
                  documentation of HER2-negative tumor: HER2-negative tumor is determined as&#xD;
                  immunohistochemistry score 0/1+ or negative by in situ hybridization&#xD;
                  (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio &lt;2 or for single probe&#xD;
                  assessment a HER2 copy number &lt;4.&#xD;
&#xD;
               -  Female participants with ER+HER2- advanced or metastatic breast cancer considered&#xD;
                  to be of childbearing potential (or have tubal ligations only) must be willing to&#xD;
                  undergo medically induced menopause by treatment with the approved LHRH agonist&#xD;
                  such as goserelin, leuprolide or equivalent agents to induce chemical menopause.&#xD;
&#xD;
               -  Participants must have at least 1 measurable lesion as defined by RECIST version&#xD;
                  1.1 that has not been previously irradiated.&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1&#xD;
&#xD;
               -  Female or male patients aged ≥ 18 years (Japan ≥ 20 years).&#xD;
&#xD;
               -  Adequate renal, liver, and bone marrow function.&#xD;
&#xD;
               -  Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1&#xD;
                  except for adverse events (AEs) not constituting a safety risk by investigator&#xD;
                  judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unmanageable ascites (limited medical treatment to control ascites is permitted, but&#xD;
             all participants with ascites require review by sponsor's medical monitor).&#xD;
&#xD;
          -  Participants with any other active malignancy within 3 years prior to enrollment,&#xD;
             except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in&#xD;
             situ.&#xD;
&#xD;
          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Prior irradiation to &gt;25% of the bone marrow.&#xD;
&#xD;
          -  ECG clinically relevant abnormalities (eg, QTc &gt;470 msec, complete LBBB, second/third&#xD;
             degree AV block, ST elevation or EKG changes suggesting myocardial infarction or&#xD;
             active myocardia ischemia).&#xD;
&#xD;
          -  Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin&#xD;
             K antagonists or factor Xa inhibitors may be allowed following discussion with the&#xD;
             Sponsor.&#xD;
&#xD;
          -  Known or suspected hypersensitivity or severe allergy to active ingredient/excipients&#xD;
             of PF-07248144.&#xD;
&#xD;
          -  Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous&#xD;
             gastric resection, lap band surgery or other GI conditions and surgeries that may&#xD;
             significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux&#xD;
             disease under treatment is allowed.&#xD;
&#xD;
          -  Pregnant or breastfeeding female participants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals dba HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center; SOCCI Pharmacy</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Phase 1 Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute / Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa cancer center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2418515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4551001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

